title: Corneal neovascularization and biological therapy.
abstract: Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions. Corneal neovascularization (NV) is a condition that can develop in response to inflammation, hypoxia, trauma, or limbal stem cell deficiency and it is a significant cause of blindness. New therapeutic options for diseases of the cornea and ocular surface are now being explored in experimental animals and clinical trials. Antibody based biologics are being tested for their ability to reduce blood and lymphatic vessel ingrowth into the cornea, and to reduce inflammation. Numerous studies have shown that biologics with specificity for VEGF A such as bevacizumab and ranibizumab (a recombinant antibody and an antibody fragment, respectively) or anti-tumor necrosis factor-α microantibody, are effective in the treatment of corneal neovascularization.
authors.affiliation: Department of Cellular and Molecular Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors.forename: O B
authors.initials: OB
authors.lastname: Voiculescu
authors.affiliation: Department of Ophthalmology, University Emergency Hospital Bucharest, Romania.
authors.forename: L M
authors.initials: LM
authors.lastname: Voinea
authors.affiliation: Department of Ophthalmology, University Emergency Hospital Bucharest, Romania.
authors.forename: C
authors.initials: C
authors.lastname: Alexandrescu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001691:Biological Therapy; D016510:Corneal Neovascularization / Q000628:therapy*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000906:Antibodies; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A
keywords: anti VEGF therapy; corneal neovascularization; vascular endothelial growth factor